Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 46,235 shares of Vor Bio’s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). The stock options have a ten-year term and exercise prices that range from $7.95 to $24.11 per share, which equal the closing price of Vor Bio’s common stock on the respective grant dates of the stock options. The options will vest over
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Biopharma (VOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
- Vor Bio to Participate in the 46th Annual TD Cowen Health Care ConferenceGlobeNewswire
- Vor Biopharma (NASDAQ:VOR) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $50.00 price target on the stock.MarketBeat
- Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
VOR
Earnings
- 11/13/25 - Miss
VOR
Sec Filings
- 3/16/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- VOR's page on the SEC website